Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
Status:
Recruiting
Trial end date:
2023-10-26
Target enrollment:
Participant gender:
Summary
This study is a prospective, multicenter, parallel, open-label, randomized, controlled,
superiority trial. It is planned to recruit 8,250 patients with multi-vessel disease(MVD),
and the patients will be followed-up for 12 months after being implanted with a drug-eluting
stent (DES) at one of 100 different centers. All patients will be randomly divided into the
treatment group and control group on a 1:1 basis, based on a complete randomization.
Phase:
Phase 4
Details
Lead Sponsor:
Harbin Medical University
Collaborators:
Chinese Society of Cardiology Lepu Medical Technology (Beijing) Co., Ltd.